Display options
Cite
Andergassen U, Kölbl AC, Hutter S, et al. Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR. Cancers (Basel). 2013;5(4):1212-20doi: 10.3390/cancers5041212.
Andergassen, U., Kölbl, A. C., Hutter, S., Friese, K., & Jeschke, U. (2013). Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR. Cancers, 5(4), 1212-20. https://doi.org/10.3390/cancers5041212
Andergassen, Ulrich, et al. "Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR." Cancers vol. 5,4 (2013): 1212-20. doi: https://doi.org/10.3390/cancers5041212
Andergassen U, Kölbl AC, Hutter S, Friese K, Jeschke U. Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR. Cancers (Basel). 2013 Sep 25;5(4):1212-20. doi: 10.3390/cancers5041212. PMID: 24202442; PMCID: PMC3875936.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2013 Sep 25;5(4):1212-20. doi: 10.3390/cancers5041212.

Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients via RT-qPCR.

Cancers

Ulrich Andergassen, Alexandra C Kölbl, Stefan Hutter, Klaus Friese, Udo Jeschke

Affiliations

  1. Department of Obstetrics and Gynaecology, Ludwig Maximilians University of Munich, Munich, Maistrasse 11, D-80337 Munich, Germany. [email protected].

PMID: 24202442 PMCID: PMC3875936 DOI: 10.3390/cancers5041212

Abstract

Breast cancer is still the most frequent cause of cancer-related death in women worldwide. Often death is not caused only by the primary tumour itself, but also by metastatic lesions. Today it is largely accepted, that these remote metastases arise out of cells, which detach from the primary tumour, enter circulation, settle down at secondary sites in the body and are called Circulating Tumour Cells (CTCs). The occurrence of such minimal residual diseases in the blood of breast cancer patients is mostly linked to a worse prognosis for therapy outcome and overall survival. Due to their very low frequency, the detection of CTCs is, still a technical challenge. RT-qPCR as a highly sensitive method could be an approach for CTC-detection from peripheral blood of breast cancer patients. This assumption is based on the fact that CTCs are of epithelial origin and therefore express a different gene panel than surrounding blood cells. For the technical approach it is necessary to identify appropriate marker genes and to correlate their gene expression levels to the number of tumour cells within a sample in an in vitro approach. After that, samples from adjuvant and metastatic patients can be analysed. This approach may lead to new concepts in diagnosis and treatment.

References

  1. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):120-5 - PubMed
  2. Recent Results Cancer Res. 2012;195:25-39 - PubMed
  3. Clin Cancer Res. 1999 Aug;5(8):1950-60 - PubMed
  4. Breast Cancer Res. 2012 Oct 22;14(5):R133 - PubMed
  5. Cancer. 1999 Dec 1;86(11):2189-91 - PubMed
  6. J Biol Chem. 2005 May 20;280(20):19543-50 - PubMed
  7. Br J Cancer. 2006 Jan 16;94(1):8-12 - PubMed
  8. Nat Rev Cancer. 2004 Jun;4(6):448-56 - PubMed
  9. Clin Lab. 2012;58(5-6):373-84 - PubMed
  10. Clin Cancer Res. 2008 May 1;14(9):2593-600 - PubMed
  11. Biochim Biophys Acta. 2012 Dec;1826(2):350-6 - PubMed
  12. Breast Cancer Res. 2012 Aug 15;14(4):R118 - PubMed
  13. Head Neck Pathol. 2012 Jul;6 Suppl 1:S63-74 - PubMed
  14. Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 - PubMed
  15. Semin Oncol. 2012 Feb;39(1):47-57 - PubMed
  16. N Engl J Med. 2013 Mar 28;368(13):1199-209 - PubMed
  17. Breast Care (Basel). 2012 Feb;7(1):7-12 - PubMed
  18. Lancet Oncol. 2004 Feb;5(2):79-88 - PubMed
  19. Pathobiology. 2008;75(2):140-8 - PubMed
  20. Clin Chem. 2011 Sep;57(9):1242-55 - PubMed
  21. Methods. 2013 Jan;59(1):89-100 - PubMed
  22. Eur J Med Res. 2009 Aug 12;14(8):359-63 - PubMed
  23. Ann N Y Acad Sci. 2000 Apr;906:110-23 - PubMed
  24. Cancer Genet Cytogenet. 2010 Mar;197(2):101-6 - PubMed
  25. Nat Med. 2013 Jun;19(6):676-7 - PubMed
  26. J Mol Diagn. 2013 Jan;15(1):17-26 - PubMed
  27. Anticancer Res. 2012 Dec;32(12):5387-91 - PubMed
  28. Ann Oncol. 2013 Mar;24(3):647-54 - PubMed
  29. World J Surg. 2006 Jun;30(6):1007-13 - PubMed
  30. Br J Cancer. 2009 Aug 18;101(4):589-97 - PubMed
  31. Patholog Res Int. 2011 Jan 03;2011:621090 - PubMed
  32. Breast Cancer Res. 2008;10(5):110 - PubMed
  33. J Clin Oncol. 2007 Nov 20;25(33):5194-202 - PubMed
  34. Br J Cancer. 2010 Jan 19;102(2):276-84 - PubMed
  35. N Engl J Med. 1998 Aug 6;339(6):357-63 - PubMed
  36. Clin Lab Med. 1988 Mar;8(1):223-36 - PubMed
  37. Acta Cytol. 2012;56(6):655-60 - PubMed
  38. J Transl Med. 2012 Jul 02;10:138 - PubMed
  39. Int J Biol Markers. 2000 Jan-Mar;15(1):100-4 - PubMed
  40. Methods. 2013 Jan;59(1):126-31 - PubMed
  41. Curr Opin Hematol. 2012 Mar;19(2):82-8 - PubMed
  42. Methods. 2001 Dec;25(4):402-8 - PubMed
  43. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7276-80 - PubMed
  44. Ann Surg. 2005 Aug;242(2):281-9 - PubMed
  45. Recent Results Cancer Res. 2012;195:187-92 - PubMed
  46. Int J Cancer. 2012 Apr 1;130(7):1590-7 - PubMed
  47. Breast Cancer Res Treat. 2008 Jan;107(1):145-54 - PubMed
  48. Oncol Rep. 2009 Nov;22(5):1119-27 - PubMed
  49. Br J Cancer. 2012 Jun 5;106(12):1917-25 - PubMed
  50. Biomed Rep. 2013 Mar;1(2):231-234 - PubMed
  51. J Clin Oncol. 2006 Aug 1;24(22):3611-8 - PubMed
  52. Clin Chem. 2013 Jan;59(1):110-8 - PubMed
  53. Clin Cancer Res. 2012 Feb 15;18(4):993-1003 - PubMed
  54. Sci Transl Med. 2013 Apr 3;5(179):179ra47 - PubMed

Publication Types